Approval · Notice of Compliance 13306 · 2012
AZILECT: Notice of Compliance 13306
Issued May 28, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13306
- Date
- May 28, 2012
- Company
- Teva Pharmaceutical Industries LtdPetach Tikva, --, Israel
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Confirmation of MAO-B selectivity of Azilect (rasagliline) at the recommended doses
- Therapeutic class
- Antiparkinsonian Agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AZILECT | Not yet assigned | — |
Medicinal ingredients
- RASAGILINE MESYLATE 1 MG per TAB
- RASAGILINE MESYLATE 0.5 MG per TAB